Latest Industry Insights

Western blotting has been a core technique in molecular biology for many years, however, optimization and reproducibility can be problematic. We spoke to Dr Alexandre Lucas about the automation of western blotting and the difference this advance is making to research.

Despite the fact that herbal or plant-based medicines are widely used and trusted by the public and have been for many years, few have been approved by regulatory agencies in the Western world as prescription medicines. But why have so few botanical medicines been approved?

180 Life Sciences is exploring the use of synthetic cannabidiol (CBD) analogs as a treatment strategy for inflammation and pain, and conducting clinical research focused on repurposing anti-tumor necrosis factor across different fibrotic conditions. Technology Networks recently spoke with Dr James Woody, chief executive officer at 180 Life Sciences, to find out more about the company's research and development pipeline.

Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges”.

Here we summarize the webinar that was hosted by Monika Seidel Ph.D., in which she discussed detecting mutations with liquid biopsies in cancer diagnostics.

Liquid chromatography has proven to be an invaluable tool in analytical labs. However, despite being a “mature” technique, there are still some areas that prove problematic, leading to suboptimal results. One such area is the loss of analytes during the chromatographic process, but design innovations are aiming to overcome this problem.

Leveraging patient-generated health data (PGHD) in healthcare and clinical trials has become significantly easier with the advent of digitalization. We spoke to Alison Bourke, scientific director for real world insights at IQVIA and past president of the International Society for Pharmacoepidemiology, about how PGHD is collected, why it is useful and how we can best safeguard sensitive data.

In this industry insights piece, we explore how gene therapies represent a rapidly growing new paradigm — both therapeutically and with respect to how they are managed within the larger scope of healthcare — and how this has wide-ranging impacts on several key areas, including regulation.

To learn more about the ways that antibody tests are being used in the pandemic, Technology Networks spoke to Heather-Read Harper, European Senior Manager for Immunoassay and Clinical Chemistry at Beckman Coulter.

Technology Networks spoke with Dr Jan Hellemans, CTO and co-founder of CRO Biogazelle, as well as co-author of the MIQE guidelines, to learn why PCR-based technologies are the "workhorse" technologies for the company.